Bull Case

Advancement of Lead Asset PMN310: PMN310, a humanized monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer’s disease, is progressing through a Phase 1b trial with over 85% enrollment and no observed ARIA safety events, supporting a differentiated safety profile versus plaque-targeting competitors.

Regulatory Momentum and Fast Track Designation: PMN310 received FDA Fast Track designation in July 2025, expediting development and review, which could accelerate time-to-market if efficacy is demonstrated.

Pipeline Expansion and Platform Potential: ProMIS’s EpiSelect™ platform underpins a pipeline with IND-ready programs for ALS and Parkinson’s disease, offering optionality and potential for multiple value-creating catalysts beyond Alzheimer’s.

Strengthened Leadership and Investor Support: Board appointment of Dr. Slanix Paul Alex, with deep biopharma investment experience, and continued backing from Ally Bridge Group enhance capital markets access and strategic execution.

If PMN310 demonstrates strong efficacy and safety in upcoming clinical readouts, ProMIS could establish a competitive position in Alzheimer’s therapeutics, with platform leverage into other neurodegenerative indications and improved investor confidence supporting valuation upside.

Base Case

Clinical Execution Risk Remains High: PMN310 is still in early-stage clinical development (Phase 1b), with no efficacy data yet; timelines for interim and top-line results extend into late 2026, leaving significant uncertainty.

Limited Financial Flexibility: Operating losses are substantial ($11.8M in Q3 2025), and cash reserves ($15.4M) provide less than 18 months of runway at current burn rates, implying likely need for further dilutive capital raises.

Nasdaq Compliance and Shareholder Dilution: Reverse stock split addresses minimum bid price deficiency but does not resolve underlying business risks; further dilution is probable given ongoing R&D spend and lack of near-term revenue.

Absent near-term clinical or business catalysts, ProMIS is likely to remain dependent on external funding, with value constrained by early-stage risk, high cash burn, and limited visibility on clinical success or commercial viability.

Bear Case

Failure in Clinical Development: If PMN310 fails to demonstrate efficacy or encounters safety issues in Phase 1b/2, the company’s lead asset and primary value driver would be impaired, with no approved products to offset the loss.

Unsustainable Financial Position: Negative free cash flow yield (-2.2%), zero operating margin, and low interest coverage (0.37x) highlight structural financial weakness; inability to raise capital could force asset sales or wind-down.

Market and Regulatory Setbacks: Failure to regain or maintain Nasdaq listing, or adverse regulatory developments, could further erode investor confidence and restrict access to capital markets.

A failed clinical outcome or inability to secure additional funding would likely result in severe value destruction, with equity at risk of becoming effectively worthless given the absence of commercial-stage assets and persistent operating losses.

Overall Score

ProMIS Neurosciences is a high-risk, early-stage biotechnology company with a single clinical asset in Alzheimer’s disease and no near-term revenue. While the differentiated mechanism and regulatory momentum offer upside if clinical data are positive, the company faces critical risks from unproven efficacy, high cash burn, and dependence on external capital. The risk/reward profile is skewed to the downside until clinical and financial visibility improves.